Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo

Markos Leggas, John C. Panetta, Yanli Zhuang, John D. Schuetz, Brad Johnston, Feng Bai, Brian Sorrentino, Sheng Zhou, Peter J Houghton, Clinton F. Stewart

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

The 4-anilinoquinazoline (4-AQ) derivative gefitinib (Iressa) is an oral epidermal growth factor receptor tyrosine kinase inhibitor. Oral administration of 4-AQ molecules, such as gefitinib, inhibits ATP-binding cassette (ABC) transporter-mediated drug efflux and strongly increases the apparent bioavailability of coadministered drug molecules that are transporter substrates. Based on in vitro studies investigating 4-AQ interactions with several transporters, these effects have primarily been attributed to the inhibition of breast cancer resistance protein (BCRP; ABCG2). Although 4-AQ shows in vitro inhibition of P-glycoprotein [multidrug resistance protein (MDR1); ABCB1], the in vivo effect on this and other transporters is not known. In our studies, pretreatment of Abcg2-/- and Mdr1(a/b)-/- mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited. These results were extended to human orthologues using engineered cell lines to show that gefitinib inhibited the efflux of BCRP and MDR1 substrates and restored vincristine sensitivity in MDR1-expressing cells. Although gefitinib inhibited BCRP more potently than MDR1 (10-fold), the inhibition of both transporters occurred at clinically relevant concentrations (e.g., 1-5 μmol/L). These studies illustrate the broad implications for the therapeutic combination of gefitinib or other 4-AQ molecules with agents that are BCRP and MDR1 substrates. 4-AQ molecules may offer a means to increase the low and variable oral drug absorption of transporter substrates while decreasing interpatient variability and reversing tumor drug resistance.

Original languageEnglish (US)
Pages (from-to)4802-4807
Number of pages6
JournalCancer Research
Volume66
Issue number9
DOIs
StatePublished - May 1 2006
Externally publishedYes

Fingerprint

ATP-Binding Cassette Transporters
Pharmaceutical Preparations
P-Glycoproteins
Topotecan
P-Glycoprotein
Vincristine
gefitinib
Epidermal Growth Factor Receptor
Drug Resistance
Protein-Tyrosine Kinases
Biological Availability
Oral Administration
Breast Neoplasms
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Leggas, M., Panetta, J. C., Zhuang, Y., Schuetz, J. D., Johnston, B., Bai, F., ... Stewart, C. F. (2006). Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Research, 66(9), 4802-4807. https://doi.org/10.1158/0008-5472.CAN-05-2915

Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. / Leggas, Markos; Panetta, John C.; Zhuang, Yanli; Schuetz, John D.; Johnston, Brad; Bai, Feng; Sorrentino, Brian; Zhou, Sheng; Houghton, Peter J; Stewart, Clinton F.

In: Cancer Research, Vol. 66, No. 9, 01.05.2006, p. 4802-4807.

Research output: Contribution to journalArticle

Leggas, M, Panetta, JC, Zhuang, Y, Schuetz, JD, Johnston, B, Bai, F, Sorrentino, B, Zhou, S, Houghton, PJ & Stewart, CF 2006, 'Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo', Cancer Research, vol. 66, no. 9, pp. 4802-4807. https://doi.org/10.1158/0008-5472.CAN-05-2915
Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Research. 2006 May 1;66(9):4802-4807. https://doi.org/10.1158/0008-5472.CAN-05-2915
Leggas, Markos ; Panetta, John C. ; Zhuang, Yanli ; Schuetz, John D. ; Johnston, Brad ; Bai, Feng ; Sorrentino, Brian ; Zhou, Sheng ; Houghton, Peter J ; Stewart, Clinton F. / Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. In: Cancer Research. 2006 ; Vol. 66, No. 9. pp. 4802-4807.
@article{6cd9d7da1f4841ddbe546c9fbae51cb1,
title = "Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo",
abstract = "The 4-anilinoquinazoline (4-AQ) derivative gefitinib (Iressa) is an oral epidermal growth factor receptor tyrosine kinase inhibitor. Oral administration of 4-AQ molecules, such as gefitinib, inhibits ATP-binding cassette (ABC) transporter-mediated drug efflux and strongly increases the apparent bioavailability of coadministered drug molecules that are transporter substrates. Based on in vitro studies investigating 4-AQ interactions with several transporters, these effects have primarily been attributed to the inhibition of breast cancer resistance protein (BCRP; ABCG2). Although 4-AQ shows in vitro inhibition of P-glycoprotein [multidrug resistance protein (MDR1); ABCB1], the in vivo effect on this and other transporters is not known. In our studies, pretreatment of Abcg2-/- and Mdr1(a/b)-/- mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited. These results were extended to human orthologues using engineered cell lines to show that gefitinib inhibited the efflux of BCRP and MDR1 substrates and restored vincristine sensitivity in MDR1-expressing cells. Although gefitinib inhibited BCRP more potently than MDR1 (10-fold), the inhibition of both transporters occurred at clinically relevant concentrations (e.g., 1-5 μmol/L). These studies illustrate the broad implications for the therapeutic combination of gefitinib or other 4-AQ molecules with agents that are BCRP and MDR1 substrates. 4-AQ molecules may offer a means to increase the low and variable oral drug absorption of transporter substrates while decreasing interpatient variability and reversing tumor drug resistance.",
author = "Markos Leggas and Panetta, {John C.} and Yanli Zhuang and Schuetz, {John D.} and Brad Johnston and Feng Bai and Brian Sorrentino and Sheng Zhou and Houghton, {Peter J} and Stewart, {Clinton F.}",
year = "2006",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-05-2915",
language = "English (US)",
volume = "66",
pages = "4802--4807",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo

AU - Leggas, Markos

AU - Panetta, John C.

AU - Zhuang, Yanli

AU - Schuetz, John D.

AU - Johnston, Brad

AU - Bai, Feng

AU - Sorrentino, Brian

AU - Zhou, Sheng

AU - Houghton, Peter J

AU - Stewart, Clinton F.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - The 4-anilinoquinazoline (4-AQ) derivative gefitinib (Iressa) is an oral epidermal growth factor receptor tyrosine kinase inhibitor. Oral administration of 4-AQ molecules, such as gefitinib, inhibits ATP-binding cassette (ABC) transporter-mediated drug efflux and strongly increases the apparent bioavailability of coadministered drug molecules that are transporter substrates. Based on in vitro studies investigating 4-AQ interactions with several transporters, these effects have primarily been attributed to the inhibition of breast cancer resistance protein (BCRP; ABCG2). Although 4-AQ shows in vitro inhibition of P-glycoprotein [multidrug resistance protein (MDR1); ABCB1], the in vivo effect on this and other transporters is not known. In our studies, pretreatment of Abcg2-/- and Mdr1(a/b)-/- mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited. These results were extended to human orthologues using engineered cell lines to show that gefitinib inhibited the efflux of BCRP and MDR1 substrates and restored vincristine sensitivity in MDR1-expressing cells. Although gefitinib inhibited BCRP more potently than MDR1 (10-fold), the inhibition of both transporters occurred at clinically relevant concentrations (e.g., 1-5 μmol/L). These studies illustrate the broad implications for the therapeutic combination of gefitinib or other 4-AQ molecules with agents that are BCRP and MDR1 substrates. 4-AQ molecules may offer a means to increase the low and variable oral drug absorption of transporter substrates while decreasing interpatient variability and reversing tumor drug resistance.

AB - The 4-anilinoquinazoline (4-AQ) derivative gefitinib (Iressa) is an oral epidermal growth factor receptor tyrosine kinase inhibitor. Oral administration of 4-AQ molecules, such as gefitinib, inhibits ATP-binding cassette (ABC) transporter-mediated drug efflux and strongly increases the apparent bioavailability of coadministered drug molecules that are transporter substrates. Based on in vitro studies investigating 4-AQ interactions with several transporters, these effects have primarily been attributed to the inhibition of breast cancer resistance protein (BCRP; ABCG2). Although 4-AQ shows in vitro inhibition of P-glycoprotein [multidrug resistance protein (MDR1); ABCB1], the in vivo effect on this and other transporters is not known. In our studies, pretreatment of Abcg2-/- and Mdr1(a/b)-/- mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited. These results were extended to human orthologues using engineered cell lines to show that gefitinib inhibited the efflux of BCRP and MDR1 substrates and restored vincristine sensitivity in MDR1-expressing cells. Although gefitinib inhibited BCRP more potently than MDR1 (10-fold), the inhibition of both transporters occurred at clinically relevant concentrations (e.g., 1-5 μmol/L). These studies illustrate the broad implications for the therapeutic combination of gefitinib or other 4-AQ molecules with agents that are BCRP and MDR1 substrates. 4-AQ molecules may offer a means to increase the low and variable oral drug absorption of transporter substrates while decreasing interpatient variability and reversing tumor drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=33646404611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646404611&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-2915

DO - 10.1158/0008-5472.CAN-05-2915

M3 - Article

VL - 66

SP - 4802

EP - 4807

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 9

ER -